Literature DB >> 23880115

Younger age at diagnosis is associated with panenteric, but not more aggressive, Crohn's disease.

Eran Israeli1, John D Ryan2, Leigh-Anne Shafer2, Charles N Bernstein3.   

Abstract

BACKGROUND & AIMS: Crohn's disease (CD) diagnosed in pediatric patients has been reported to have a more aggressive phenotype and course, with a greater prevalence of upper gastrointestinal involvement, than in adults. However, studies have not accounted for differences in diagnostic tests. We aimed to discern whether, in fact, CD diagnosed in childhood has a different outcome than CD diagnosed in adults.
METHODS: We performed comprehensive medical chart reviews of 571 patients with CD (451 with complete data) who were followed in a single referral inflammatory bowel disease clinic in Winnipeg, Canada, from 1993-2012. For specific time intervals, we determined types and numbers of imaging studies performed and parameters of disease phenotype, including age at diagnosis according to the Montreal classification (A1 diagnosed <17 years of age, A2 diagnosed 17-40 years, and A3 diagnosed >40 years).
RESULTS: Within 1 year of diagnosis, a higher proportion of A1 patients had upper gastrointestinal involvement and ileocolonic (L3) disease than A2 or A3 patients. These differences could be partly accounted for by the diagnostic tests performed during this time period. Although A1 patients underwent more extensive imaging studies, they had a lower prevalence of complicated disease, particularly compared with A3 patients. After a median follow-up period of 11.1 years, complicated disease behavior (B2 [structuring] or B3 [penetrating]) was similar among the 3 groups. Nonetheless, at the end of the study period, rates of inflammatory bowel disease-related abdominal surgery were significantly lower for A1 than A2 patients (odds ratio, 0.63; 95% confidence interval, 0.41-0.98) but not for A3 patients (odds ratio, 0.71; 95% confidence interval, 0.40-1.27).
CONCLUSIONS: On the basis of a database analysis of different age groups of patients with CD, studies of disease phenotypes among different cohorts should account for different patterns of diagnostic imaging evaluation. Our data show that although children are at increased risk of panenteric disease, they are not more likely to have more complicated disease or undergo surgery than adults.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD; CI; CT; Crohn's disease; EGD; Endoscopy; IBD; Inflammatory Bowel Disease; MRI; Montreal Classification; OR; Progression; Radiology; SBBS; UGI; computed tomography; confidence interval; esophagogastroduodenoscopy; inflammatory bowel disease; magnetic resonance imaging; odds ratio; small bowel barium series; upper gastrointestinal

Mesh:

Year:  2013        PMID: 23880115     DOI: 10.1016/j.cgh.2013.06.027

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  9 in total

1.  Characterization of inflammatory bowel disease in elderly hospitalized patients in a large central Canadian Health region.

Authors:  Peter Stepaniuk; Charles N Bernstein; Zoann Nugent; Harminder Singh
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04-15

2.  Serum protein profiling of adults and children with Crohn disease.

Authors:  Anna Vaiopoulou; Maria Gazouli; Aggeliki Papadopoulou; Athanassios K Anagnostopoulos; George Karamanolis; George E Theodoropoulos; Amosy M'Koma; George T Tsangaris
Journal:  J Pediatr Gastroenterol Nutr       Date:  2015-01       Impact factor: 2.839

3.  Risk Factors for Surgery in Pediatric Patients with Crohn's Disease.

Authors:  Rayna Rumenova Shentova-Eneva; Denitza Kofinova; Petyo Hadzhiyski; Ekaterina Ivanova-Todorova; Penka Yaneva; Elena Lazarova; Mila Baycheva
Journal:  Med Princ Pract       Date:  2022-01-27       Impact factor: 2.132

Review 4.  Inflammatory bowel disease course in Crohn's disease: is the natural history changing?

Authors:  Petra A Golovics; Michael D Mandel; Barbara D Lovasz; Peter L Lakatos
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

5.  The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.

Authors:  Matthew W Carroll; M Ellen Kuenzig; David R Mack; Anthony R Otley; Anne M Griffiths; Gilaad G Kaplan; Charles N Bernstein; Alain Bitton; Sanjay K Murthy; Geoffrey C Nguyen; Kate Lee; Jane Cooke-Lauder; Eric I Benchimol
Journal:  J Can Assoc Gastroenterol       Date:  2018-11-02

6.  A Case of a Two-Month-Old Boy Diagnosed with Infantile Crohn's Disease Based on an Atypical Perianal Lesion.

Authors:  Kengo Nakaya; Yasushi Iinuma; Yutaka Hirayama; Yu Sugai; Shotaro Taki
Journal:  Case Rep Pediatr       Date:  2020-12-09

7.  Long-term Outcomes and Risk Factors for Reoperation After Surgical Treatment for Gastrointestinal Crohn Disease According to Anti-tumor Necrosis Factor-α Antibody Use: 35 Years of Experience at a Single Institute in Korea.

Authors:  Sang Mok Lee; Eon Chul Han; Seung-Bum Ryoo; Heung-Kwon Oh; Eun Kyung Choe; Sang Hui Moon; Joo Sung Kim; Hyun Chae Jung; Kyu Joo Park
Journal:  Ann Coloproctol       Date:  2015-08-31

8.  Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study.

Authors:  Ruth Ann Marrie; Lesley Graff; John R Walker; John D Fisk; Scott B Patten; Carol A Hitchon; Lisa M Lix; James Bolton; Jitender Sareen; Alan Katz; Lindsay I Berrigan; James J Marriott; Alexander Singer; Renée El-Gabalawy; Christine A Peschken; Ryan Zarychanski; Charles N Bernstein
Journal:  JMIR Res Protoc       Date:  2018-01-17

9.  Host immunoglobulin G selectively identifies pathobionts in pediatric inflammatory bowel diseases.

Authors:  Heather Armstrong; Misagh Alipour; Rosica Valcheva; Michael Bording-Jorgensen; Juan Jovel; Deenaz Zaidi; Prachi Shah; Yuefei Lou; Cory Ebeling; Andrew L Mason; Dawson Lafleur; Jeremy Jerasi; Gane K-S Wong; Karen Madsen; Matthew W Carroll; Hien Q Huynh; Levinus A Dieleman; Eytan Wine
Journal:  Microbiome       Date:  2019-01-03       Impact factor: 14.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.